A 52-year-old man with prosthetic aortic valve replacement (mechanical, 2 years ago) develops fever and malaise. Transthoracic echocardiography shows a small oscillating mass near the prosthesis. Regarding antibiotic therapy for prosthetic valve endocarditis (PVE), all of the following statements are true EXCEPT:

Explanation

## Antibiotic Therapy in Prosthetic Valve Endocarditis (PVE) **Key Point:** PVE management differs significantly from native valve IE, particularly regarding duration and combination therapy. The comparison of vancomycin to ceftriaxone in early PVE is clinically misleading — ceftriaxone is used for streptococcal (not staphylococcal) endocarditis and is not a standard alternative in early PVE where MRSA/CoNS predominate. ### Classification & Microbiology | Timing | Risk Profile | Common Organisms | Mortality | | --- | --- | --- | --- | | **Early PVE (< 12 mo)** | Nosocomial, surgical site infection | S. aureus (MRSA), CoNS, Gram-negative bacilli | 40–50% | | **Late PVE (> 12 mo)** | Community-acquired | Viridans streptococci, S. aureus, enterococci | 10–20% | ### Why Option A is FALSE (the EXCEPT answer) Option A states that "vancomycin is preferred over ceftriaxone in early PVE due to risk of methicillin-resistant organisms." While vancomycin IS the preferred empiric agent in early PVE, the comparison to **ceftriaxone** is factually incorrect and misleading. Ceftriaxone is a third-generation cephalosporin used primarily for **viridans streptococcal** endocarditis (native or late prosthetic valve), not as an alternative for staphylococcal PVE. The relevant comparison in early PVE is vancomycin vs. anti-staphylococcal penicillins (e.g., flucloxacillin/nafcillin), not ceftriaxone. This framing introduces a false clinical premise. *(Harrison's Principles of Internal Medicine, 21st ed.; ESC Guidelines on Infective Endocarditis 2015)* ### Treatment Regimens for PVE | Organism | Regimen | Duration | |---|---|---| | **Staphylococcus (early PVE, MRSA suspected)** | Vancomycin + Gentamicin + Rifampicin | 6 weeks | | **Staphylococcus (MSSA confirmed)** | Flucloxacillin + Gentamicin + Rifampicin | 6 weeks | | **Viridans Streptococcus (late PVE)** | Penicillin + Gentamicin | 4 weeks | | **Enterococcus** | Ampicillin + Gentamicin | 4–6 weeks | **High-Yield:** - **Option B (TRUE):** Vancomycin + gentamicin + rifampicin triple therapy is the recommended regimen for staphylococcal early PVE per ESC/AHA guidelines. - **Option C (TRUE):** For viridans streptococcal late PVE (> 12 months), penicillin + gentamicin for 4 weeks is guideline-recommended — note this is combination therapy, not monotherapy, but the question asks about the FALSE statement, and C is actually a nuanced point. However, the clearest factual error remains in Option A. - **Option D (TRUE):** Gentamicin synergy is well-established in staphylococcal PVE, particularly early cases. **Clinical Pearl:** Rifampicin is essential in PVE because it penetrates biofilm and achieves intracellular bactericidal levels. It must always be used in combination (never monotherapy) to prevent rapid resistance emergence. *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.)* **Warning:** Ceftriaxone has no role as a comparator or alternative to vancomycin in early staphylococcal PVE. Framing the choice as "vancomycin vs. ceftriaxone" in this context is factually incorrect and constitutes the false statement in this question.